![Simon Jones PhD, BSc (Hons) FLSW MAE FRSB](https://profiles-cardiff.imgix.net/attachments/4242?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Simon Jones
PhD, BSc (Hons) FLSW MAE FRSB
- Sylwebydd y cyfryngau
Timau a rolau for Simon Jones
Cyd-gyfarwyddwr, Sefydliad Ymchwil Imiwnedd Systemau
Trosolwyg
Simon Jones yw Cyd-Gyfarwyddwr y Sefydliad Ymchwil Imiwnedd Systemau a Chanolfan Hodge ar gyfer Niwrowyddoniaeth Drosiadol ym Mhrifysgol Caerdydd. Fel sy'n awdurdod rhyngwladol ar fioleg cytokine, mae wedi arloesi datblygiadau sylweddol yn ein dealltwriaeth o glefydau llidiol wedi'u cyfryngu ag imiwnedd (ee, arthritis gwynegol) a'u triniaeth trwy sefydlu paradeim newydd sydd wedi newid ein gwybodaeth o sut mae cytocinau yn llywio llid. Darganfu fod rhyngleukin-6 (IL-6) yn gweithredu trwy ddau fecanwaith signalau gwahanol, gan arwain at ddatblygu atalyddion dewisol traws-signalu IL-6 (ee, olamkicept) a ddefnyddir bellach fel meddyginiaethau biolegol. Mae ei ymchwil wedi chwyldroi ymchwil fferyllol o ymyriadau IL-6 eraill (ee, tocilizumab), gan gyflwyno cysyniadau sy'n egluro sut mae cwrs clefyd yn cael ei newid gan fecanweithiau sy'n mireinio dehongliad cellog ciwiau cytokine.
Mae Jones yn uwch gynghorydd i'r sector fferyllol ar feddyginiaethau biolegol. Roedd yn aelod o Fwrdd Cynghori Trosiadol Actemra, gan werthuso cyflwyniad clinigol tocilizumab (Roche), ac mae'n hyfforddi clinigwyr, a gweithwyr gofal iechyd proffesiynol ar weithredoedd therapïau targedu cytokine. Mae Jones yn gwasanaethu ar baneli dyfarnu grantiau (e.e., UKRI-MRC), byrddau golygyddol, a phwyllgorau sy'n cynghori strategaethau ariannu'r llywodraeth ac elusennau. Roedd Jones yn Ddeon Ymchwil (Ysgol Meddygaeth, Prifysgol Caerdydd). Mae'n chwarae rolau arweinyddiaeth weithredol yn y Gymdeithas Ryngwladol Cytokine ac Interferon (ICIS), gan gadeirio eu cynhadledd flynyddol Cytokines2021 a chyfarfod Cytokines2026 sydd ar ddod. Dyfynnir Jones yn uchel (H-mynegai: 77) a derbyniodd Wobr Boltzmann gan yr ICIS am ei ymchwil cytokine. Cafodd ei ethol yn Gymrawd Cymdeithas Ddysgedig Cymru (2019), ac yn Aelod o'r Academia Europaea (2021).
Cyhoeddiad
2025
- Rose‐John, S. and Jones, S. A. 2025. More and more pleiotropy within the IL ‐6 family of cytokines. The FEBS Journal 292(3), pp. 519-522. (10.1111/febs.17355)
2024
- Odd, D., Sabir, H., Jones, S. A., Gale, C. and Chakkarapani, E. 2024. Risk factors for infection and outcomes in infants with neonatal encephalopathy: a cohort study. Pediatric Research 96, pp. 785-791. (10.1038/s41390-024-03157-9)
2023
- Millrine, D. et al. 2023. Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements. The Journal of Immunology 211(2), pp. 274-286. (10.4049/jimmunol.2300114)
- Clement, M. et al. 2023. Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1. eLife 12, article number: e79165. (10.7554/eLife.79165)
- Millrine, D., Rice, C. M., Fernandez, J. U. and Jones, S. A. 2023. Tracking the host response to infection in peritoneal models of acute resolving inflammation. In: Jenkins, B. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York: Springer, pp. 81-95., (10.1007/978-1-0716-3331-1_7)
- Karhunen, V. et al. 2023. The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. BMJ Medicine 2(1), article number: e000157. (10.1136/bmjmed-2022-000157)
2022
- Millrine, D., Jenkins, R. H., Hughes, S. T. O. and Jones, S. A. 2022. Making sense of IL-6 signalling cues in pathophysiology. FEBS Letters 596(5), pp. 567-588. (10.1002/1873-3468.14201)
- Misheva, M. et al. 2022. Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation. Nature Communications 13(1), article number: 139. (10.1038/s41467-021-27766-8)
2021
- Jenkins, R. H., Hughes, S. T., Cardus Figueras, A. and Jones, S. A. 2021. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 148, article number: 155684. (10.1016/j.cyto.2021.155684)
- Heise, D. et al. 2021. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Science Signaling 14(696), article number: eabc3480. (10.1126/scisignal.abc3480)
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
- Jones, S. A. and Hunter, C. A. 2021. Is IL-6 a key cytokine target for therapy in COVID-19?. Nature Reviews Immunology 21(6), pp. 337–339. (10.1038/s41577-021-00553-8)
2020
- Jones, S. A., Bryant, C., Lloyd, C. M., McInnes, I. and O'Neill, L. 2020. A vision for cytokine biology with 20/20 clarity. Function 2(1), article number: zqaa042. (10.1093/function/zqaa042)
- Ponsford, M. J. et al. 2020. Cardiometabolic traits, sepsis, and severe COVID-19. Circulation 142(18), pp. 1791–1793. (10.1161/CIRCULATIONAHA.120.050753)
- Lucchesi, D. et al. 2020. Impaired IL‐27 mediated control of CD4+ T cell function impacts on ectopic lymphoid structure formation in patients with Sjögren's Syndrome. Arthritis and Rheumatology 72(9), pp. 1559-1570., article number: Volume72, Issue9 September 2020 Pages 1559-1570. (10.1002/art.41289)
- Harbour, S. N. et al. 2020. Th17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Science Immunology 5(49), article number: eaaw2262. (10.1126/sciimmunol.aaw2262)
- O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1(1), article number: zqaa002. (10.1093/function/zqaa002)
2019
- Jones, H. J., Hubbard, L., Mitchell, R. E., Jones, S. A., Williams, N. M., Zammit, S. and Hall, J. 2019. Association of genetic risk for rheumatoid arthritis with cognitive and psychiatric phenotypes across childhood and adolescence. JAMA Network Open 2(6), pp. -., article number: e196118. (10.1001/jamanetworkopen.2019.6118)
- Twohig, J. P. et al. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20, pp. 458-470. (10.1038/s41590-019-0350-0)
- Jones, S. A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E. H. and McInnes, I. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
- Takeuchi, T., Smolen, J. S., Choy, E., Aletaha, D., McInnes, I. and Jones, S. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
- Smolen, J. S., Aletaha, D., Choy, E., Jones, S., Takeuchi, T. and McInnes, I. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
- Choy, E., Jones, S., Aletaha, D., Takeuchi, T., McInnes, I. and Smolen, J. S. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
2018
- Rivellese, F. et al. 2018. Mast cells in early rheumatoid arthritis associate with disease severity and support B-cell autoantibody production. Annals of the Rheumatic Diseases 77(12), pp. 1773-1781. (10.1136/annrheumdis-2018-213418)
- Jones, S. A. and Jenkins, B. J. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Reviews Immunology 18, pp. 773-789. (10.1038/s41577-018-0066-7)
- Jones, G., Hill, D., Cardus Figueras, A. and Jones, S. 2018. IL-27 - a double agent in the IL-6 family. Clinical and Experimental Immunology 193(1), pp. 37-46. (10.1111/cei.13116)
- Fernandez, J. U., Millrine, D. and Jones, S. 2018. Tracking competent host defence to chronic inflammation: An In Vivo model of peritonitis. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 1725. Methods in Molecular Biology New York, NY: Springer, pp. 65-75., (10.1007/978-1-4939-7568-6_6)
2017
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10(507), article number: eaan2787. (10.1126/scisignal.aan2787)
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Catar, R. et al. 2017. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. Journal of the American Society of Nephrology 28(4), pp. 1188-1199. (10.1681/ASN.2015101169)
- Dutzan, N. et al. 2017. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. Immunity 46(1), pp. 133-147. (10.1016/j.immuni.2016.12.010)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2(1) (10.12688/wellcomeopenres.10308.1)
2016
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
- Jones, G., Hill, D. and Jones, S. 2016. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Frontiers in Immunology 7, pp. 1-13., article number: 401. (10.3389/fimmu.2016.00401)
- Liao, C. et al. 2016. IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation. European Journal of Immunology 46(9), pp. 2222-2232. (10.1002/eji.201646528)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Liu, X., Jones, G. W., Choy, E. H. and Jones, S. A. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
- Jones, G. W. and Jones, S. A. 2016. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147(2), pp. 141-151. (10.1111/imm.12554)
2015
- Lacroix, M. et al. 2015. Novel insights into IL-6 cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. Journal of Biological Chemistry 290, pp. 26943-26953. (10.1074/jbc.M115.682138)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Beyer, C. et al. 2015. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases 74(6), pp. 1317-1324. (10.1136/annrheumdis-2013-204401)
- Hunter, C. A. and Jones, S. A. 2015. IL-6 as a keystone cytokine in health and disease. Nature Immunology 16(5), pp. 448-457. (10.1038/ni.3153)
2014
- Rosser, E. C. et al. 2014. Regulatory B cells are induced by gut microbiota- driven interleukin-1β and interleukin-6 production. Nature Medicine 20, pp. 1334-1339. (10.1038/nm.3680)
- Garbers, C. et al. 2014. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochimica et Biophysica Acta - Molecular Basis of Disease 1842(9), pp. 1485-1494. (10.1016/j.bbadis.2014.05.018)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Pitzalis, C., Jones, G. W., Bombardieri, M. and Jones, S. A. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology 14(7), pp. 447-462. (10.1038/nri3700)
- Rosas, M. et al. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 344(6184), pp. 645-648. (10.1126/science.1251414)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
2013
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Orr, S. J. et al. 2013. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. PLoS Pathogens 9(5), article number: e1003357. (10.1371/journal.ppat.1003357)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
- Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
- Chakraborty, M., McGreal, E. P., Davies, P. L., Nowell, M. A., Jones, S. A. and Kotecha, S. 2013. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. Neonatology 104(3), pp. 161-167. (10.1159/000351015)
2012
- McDonald, J. U., Rosas, M., Brown, G. D., Jones, S. A. and Taylor, P. R. 2012. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS ONE 7(9), article number: e45781. (10.1371/journal.pone.0045781)
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- O'Connor, R. A., Floess, S., Huehn, J., Jones, S. A. and Anderton, S. M. 2012. Foxp3+Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production. European Journal of Immunology 42(5), pp. 1174-1179. (10.1002/eji.201142216)
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
2011
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
- McDonald, J. U. et al. 2011. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. The FASEB Journal 25(6), pp. 1972-1982. (10.1096/fj.10-178517)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Rosas, M. et al. 2011. Hoxb8 conditionally immortalised macrophage lines model inflammatory monocytic cells with important similarity to dendritic cells. European Journal of Immunology 41(2), pp. 356-365. (10.1002/eji.201040962)
- Liddiard, K., Rosas, M., Davies, L. C., Jones, S. A. and Taylor, P. R. 2011. Macrophage heterogeneity and acute inflammation. European Journal of Immunology 41(9), pp. 2503-2508. (10.1002/eji.201141743)
- Davies, L. C., Rosas, M., Smith, P. J., Fraser, D. J., Jones, S. A. and Taylor, P. R. 2011. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. European Journal of Immunology 41(8), pp. 2155-2164. (10.1002/eji.201141817)
- Kennedy, C. L. et al. 2011. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. The Journal of Pathology 225(2), pp. 255-264. (10.1002/path.2933)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Jones, S. A., Scheller, J. and Rose-John, S. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121(9), pp. 3375-3383. (10.1172/JCI57158)
- McGreal, E. P., Chakraborty, M., Winter, V. T., Jones, S. A., Coalson, J. J. and Kotecha, S. 2011. Dynamic expression of IL-6 trans-signalling molecules in the lungs of preterm baboons undergoing mechanical ventilation. Neonatology 100(2), pp. 130-138. (10.1159/000322148)
2010
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Leggate, M., Nowell, M. A., Jones, S. A. and Nimmo, M. N. 2010. The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress and Chaperones 15(6), pp. 827-833. (10.1007/s12192-010-0192-z)
- McGreal, E. P. et al. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease 1802(7-8), pp. 649-658. (10.1016/j.bbadis.2010.04.005)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
2009
- Cash, H. et al. 2009. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. The Journal of Rheumatology 37(1), pp. 60-70. (10.3899/jrheum.090194)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
2008
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Longhi, M. P. et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Dioszeghy, V. et al. 2008. 12/15-lipoxygenase regulates the inflammatory response to bacterial products in vivo. The Journal of Immunology 181(9), pp. 6514-6524.
2007
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
2006
- Dimitrov, S. et al. 2006. Sleep enhances IL-6 trans-signaling in humans. The FASEB Journal 20(12), pp. 2174-2176. (10.1096/fj.06-5754fje)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Peake, N. J. et al. 2006. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45(12), pp. 1485-1489. (10.1093/rheumatology/kel154)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
2005
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
2004
- McLoughlin, R. M. et al. 2004. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. The Journal of Immunology 172, pp. 5676-83.
2003
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
2001
- Robson, R. L., McLoughlin, R. M., Witowski, J., Loetscher, P., Wilkinson, T. S., Jones, S. A. and Topley, N. 2001. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo. The Journal of Immunology 167(2), pp. 1028-1038.
- Hurst, S. M. et al. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6), pp. 705-714. (10.1016/S1074-7613(01)00151-0)
Articles
- Rose‐John, S. and Jones, S. A. 2025. More and more pleiotropy within the IL ‐6 family of cytokines. The FEBS Journal 292(3), pp. 519-522. (10.1111/febs.17355)
- Odd, D., Sabir, H., Jones, S. A., Gale, C. and Chakkarapani, E. 2024. Risk factors for infection and outcomes in infants with neonatal encephalopathy: a cohort study. Pediatric Research 96, pp. 785-791. (10.1038/s41390-024-03157-9)
- Millrine, D. et al. 2023. Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements. The Journal of Immunology 211(2), pp. 274-286. (10.4049/jimmunol.2300114)
- Clement, M. et al. 2023. Inhibitory IL-10-producing CD4+ T cells are T-bet-dependent and facilitate cytomegalovirus persistence via coexpression of arginase-1. eLife 12, article number: e79165. (10.7554/eLife.79165)
- Karhunen, V. et al. 2023. The interplay between inflammatory cytokines and cardiometabolic disease: bi-directional mendelian randomisation study. BMJ Medicine 2(1), article number: e000157. (10.1136/bmjmed-2022-000157)
- Millrine, D., Jenkins, R. H., Hughes, S. T. O. and Jones, S. A. 2022. Making sense of IL-6 signalling cues in pathophysiology. FEBS Letters 596(5), pp. 567-588. (10.1002/1873-3468.14201)
- Misheva, M. et al. 2022. Oxylipin metabolism is controlled by mitochondrial β-oxidation during bacterial inflammation. Nature Communications 13(1), article number: 139. (10.1038/s41467-021-27766-8)
- Jenkins, R. H., Hughes, S. T., Cardus Figueras, A. and Jones, S. A. 2021. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 148, article number: 155684. (10.1016/j.cyto.2021.155684)
- Heise, D. et al. 2021. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Science Signaling 14(696), article number: eabc3480. (10.1126/scisignal.abc3480)
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
- Jones, S. A. and Hunter, C. A. 2021. Is IL-6 a key cytokine target for therapy in COVID-19?. Nature Reviews Immunology 21(6), pp. 337–339. (10.1038/s41577-021-00553-8)
- Jones, S. A., Bryant, C., Lloyd, C. M., McInnes, I. and O'Neill, L. 2020. A vision for cytokine biology with 20/20 clarity. Function 2(1), article number: zqaa042. (10.1093/function/zqaa042)
- Ponsford, M. J. et al. 2020. Cardiometabolic traits, sepsis, and severe COVID-19. Circulation 142(18), pp. 1791–1793. (10.1161/CIRCULATIONAHA.120.050753)
- Lucchesi, D. et al. 2020. Impaired IL‐27 mediated control of CD4+ T cell function impacts on ectopic lymphoid structure formation in patients with Sjögren's Syndrome. Arthritis and Rheumatology 72(9), pp. 1559-1570., article number: Volume72, Issue9 September 2020 Pages 1559-1570. (10.1002/art.41289)
- Harbour, S. N. et al. 2020. Th17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Science Immunology 5(49), article number: eaaw2262. (10.1126/sciimmunol.aaw2262)
- O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1(1), article number: zqaa002. (10.1093/function/zqaa002)
- Jones, H. J., Hubbard, L., Mitchell, R. E., Jones, S. A., Williams, N. M., Zammit, S. and Hall, J. 2019. Association of genetic risk for rheumatoid arthritis with cognitive and psychiatric phenotypes across childhood and adolescence. JAMA Network Open 2(6), pp. -., article number: e196118. (10.1001/jamanetworkopen.2019.6118)
- Twohig, J. P. et al. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20, pp. 458-470. (10.1038/s41590-019-0350-0)
- Jones, S. A., Takeuchi, T., Aletaha, D., Smolen, J., Choy, E. H. and McInnes, I. 2019. Interleukin 6: the biology behind the therapy. Considerations in Medicine 2 (10.1136/conmed-2018-000005)
- Takeuchi, T., Smolen, J. S., Choy, E., Aletaha, D., McInnes, I. and Jones, S. 2019. Considering new lessons about the use of IL-6 inhibitors in arthritis. BMJ Considerations in Medicine 2(1), pp. 7-11. (10.1136/conmed-2018-000002)
- Smolen, J. S., Aletaha, D., Choy, E., Jones, S., Takeuchi, T. and McInnes, I. 2019. Targeting IL-6: a review of data. BMJ Considerations in Medicine 2(1), pp. 12-18. (10.1136/conmed-2018-000003)
- Choy, E., Jones, S., Aletaha, D., Takeuchi, T., McInnes, I. and Smolen, J. S. 2019. IL-6: To immunity and beyond. BMJ Considerations in Medicine 2(1), pp. 19-23. (10.1136/conmed-2018-000004)
- Rivellese, F. et al. 2018. Mast cells in early rheumatoid arthritis associate with disease severity and support B-cell autoantibody production. Annals of the Rheumatic Diseases 77(12), pp. 1773-1781. (10.1136/annrheumdis-2018-213418)
- Jones, S. A. and Jenkins, B. J. 2018. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nature Reviews Immunology 18, pp. 773-789. (10.1038/s41577-018-0066-7)
- Jones, G., Hill, D., Cardus Figueras, A. and Jones, S. 2018. IL-27 - a double agent in the IL-6 family. Clinical and Experimental Immunology 193(1), pp. 37-46. (10.1111/cei.13116)
- Lauder, S. N. et al. 2017. Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling 10(507), article number: eaan2787. (10.1126/scisignal.aan2787)
- Stacey, M. A. et al. 2017. The antiviral restriction factor IFN-induced transmembrane protein 3 prevents cytokine-driven CMV pathogenesis. Journal of Clinical Investigation 127(4), pp. 1463-1474. (10.1172/JCI84889)
- Catar, R. et al. 2017. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. Journal of the American Society of Nephrology 28(4), pp. 1188-1199. (10.1681/ASN.2015101169)
- Dutzan, N. et al. 2017. On-going mechanical damage from mastication drives homeostatic Th17 cell responses at the oral barrier. Immunity 46(1), pp. 133-147. (10.1016/j.immuni.2016.12.010)
- Lauder, S. N. et al. 2017. Myeloid 12/15-LOX regulates B cell numbers and innate immune antibody levels in vivo. Wellcome Open Research 2(1) (10.12688/wellcomeopenres.10308.1)
- Clement, M. et al. 2016. Cytomegalovirus-specific IL-10-producing CD4+ T cells are governed by type-I IFN-induced IL-27 and promote virus persistence. Plos Pathogens 12(12), article number: e1006050. (10.1371/journal.ppat.1006050)
- Jones, G., Hill, D. and Jones, S. 2016. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Frontiers in Immunology 7, pp. 1-13., article number: 401. (10.3389/fimmu.2016.00401)
- Liao, C. et al. 2016. IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation. European Journal of Immunology 46(9), pp. 2222-2232. (10.1002/eji.201646528)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Liu, X., Jones, G. W., Choy, E. H. and Jones, S. A. 2016. The biology behind interleukin-6 targeted interventions. Current Opinion in Rheumatology 28(2), pp. 152-160. (10.1097/BOR.0000000000000255)
- Jones, G. W. and Jones, S. A. 2016. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147(2), pp. 141-151. (10.1111/imm.12554)
- Lacroix, M. et al. 2015. Novel insights into IL-6 cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. Journal of Biological Chemistry 290, pp. 26943-26953. (10.1074/jbc.M115.682138)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Beyer, C. et al. 2015. Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. Annals of the Rheumatic Diseases 74(6), pp. 1317-1324. (10.1136/annrheumdis-2013-204401)
- Hunter, C. A. and Jones, S. A. 2015. IL-6 as a keystone cytokine in health and disease. Nature Immunology 16(5), pp. 448-457. (10.1038/ni.3153)
- Rosser, E. C. et al. 2014. Regulatory B cells are induced by gut microbiota- driven interleukin-1β and interleukin-6 production. Nature Medicine 20, pp. 1334-1339. (10.1038/nm.3680)
- Garbers, C. et al. 2014. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochimica et Biophysica Acta - Molecular Basis of Disease 1842(9), pp. 1485-1494. (10.1016/j.bbadis.2014.05.018)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Pitzalis, C., Jones, G. W., Bombardieri, M. and Jones, S. A. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nature Reviews Immunology 14(7), pp. 447-462. (10.1038/nri3700)
- Rosas, M. et al. 2014. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. Science 344(6184), pp. 645-648. (10.1126/science.1251414)
- Jones, S. A., Fraser, D. J., Fielding, C. A. and Jones, G. W. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30(4), pp. 564-574. (10.1093/ndt/gfu233)
- Fielding, C. A. et al. 2014. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40(1), pp. 40-50. (10.1016/j.immuni.2013.10.022)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Fielding, C. A., Jones, G. W., Taylor, P. R., Jenkins, B. J., Topley, N. and Jones, S. A. 2013. IL-6 regulation of Th1 responses drives fibrosis in unresolved inflammation [Abstract]. Cytokine 63(3), pp. 262. (10.1016/j.cyto.2013.06.082)
- Davies, L. C. et al. 2013. Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation. Nature Communications 4, article number: 1886. (10.1038/ncomms2877)
- Orr, S. J. et al. 2013. LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. PLoS Pathogens 9(5), article number: e1003357. (10.1371/journal.ppat.1003357)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
- Choy, E. H. S., Kavanaugh, A. and Jones, S. A. 2013. The problem of choice: current biologic agents and future prospects in RA [review]. Nature Reviews Rheumatology 9(3), pp. 154-163. (10.1038/nrrheum.2013.8)
- Chakraborty, M., McGreal, E. P., Davies, P. L., Nowell, M. A., Jones, S. A. and Kotecha, S. 2013. Role of interleukin-6, its receptor and soluble gp130 in chronic lung disease of prematurity. Neonatology 104(3), pp. 161-167. (10.1159/000351015)
- McDonald, J. U., Rosas, M., Brown, G. D., Jones, S. A. and Taylor, P. R. 2012. Differential dependencies of monocytes and neutrophils on dectin-1, dectin-2 and complement for the recognition of fungal particles in inflammation. PLoS ONE 7(9), article number: e45781. (10.1371/journal.pone.0045781)
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- O'Connor, R. A., Floess, S., Huehn, J., Jones, S. A. and Anderton, S. M. 2012. Foxp3+Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production. European Journal of Immunology 42(5), pp. 1174-1179. (10.1002/eji.201142216)
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Colmont, C. S. et al. 2011. Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrology Dialysis Transplantation 26(12), pp. 4079-4090. (10.1093/ndt/gfr217)
- McDonald, J. U. et al. 2011. In vivo functional analysis and genetic modification of in vitro-derived mouse neutrophils. The FASEB Journal 25(6), pp. 1972-1982. (10.1096/fj.10-178517)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5), pp. 368-374. (10.1136/thx.2010.150318)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Rosas, M. et al. 2011. Hoxb8 conditionally immortalised macrophage lines model inflammatory monocytic cells with important similarity to dendritic cells. European Journal of Immunology 41(2), pp. 356-365. (10.1002/eji.201040962)
- Liddiard, K., Rosas, M., Davies, L. C., Jones, S. A. and Taylor, P. R. 2011. Macrophage heterogeneity and acute inflammation. European Journal of Immunology 41(9), pp. 2503-2508. (10.1002/eji.201141743)
- Davies, L. C., Rosas, M., Smith, P. J., Fraser, D. J., Jones, S. A. and Taylor, P. R. 2011. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. European Journal of Immunology 41(8), pp. 2155-2164. (10.1002/eji.201141817)
- Kennedy, C. L. et al. 2011. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. The Journal of Pathology 225(2), pp. 255-264. (10.1002/path.2933)
- Clark, S. R. et al. 2011. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood 117(6), pp. 2033-2043. (10.1182/blood-2010-04-278887)
- Jones, S. A., Scheller, J. and Rose-John, S. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Journal of Clinical Investigation 121(9), pp. 3375-3383. (10.1172/JCI57158)
- McGreal, E. P., Chakraborty, M., Winter, V. T., Jones, S. A., Coalson, J. J. and Kotecha, S. 2011. Dynamic expression of IL-6 trans-signalling molecules in the lungs of preterm baboons undergoing mechanical ventilation. Neonatology 100(2), pp. 130-138. (10.1159/000322148)
- Stumhofer, J. S. et al. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology 11(12), pp. 1119-1126. (10.1038/ni.1957)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lauder, S. N., Smart, K., Ondondo, B., Fielding, C. A., Godkin, A. J., Jones, S. A. and Gallimore, A. M. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131(S1), pp. 186. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Coles, B., Colmont, C. S., Fielding, C. A., Kift-Morgan, A., Hams, E., Topley, N. and Jones, S. A. 2010. Local manipulation of IL-6 trans-signaling therapeutically enhances anti-microbial host defense [Abstract]. Cytokine 52(1-2), pp. 80-81. (10.1016/j.cyto.2010.07.335)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Leggate, M., Nowell, M. A., Jones, S. A. and Nimmo, M. N. 2010. The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling. Cell Stress and Chaperones 15(6), pp. 827-833. (10.1007/s12192-010-0192-z)
- McGreal, E. P. et al. 2010. Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease 1802(7-8), pp. 649-658. (10.1016/j.bbadis.2010.04.005)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
- Cash, H. et al. 2009. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. The Journal of Rheumatology 37(1), pp. 60-70. (10.3899/jrheum.090194)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Morgan, A. H. et al. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. Journal of Biological Chemistry 284(32), pp. 21185-21191. (10.1074/jbc.M109.021634)
- Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183(1), pp. 506-517. (10.4049/jimmunol.0802909)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Jenkins, B. J. et al. 2008. Differential roles of IL-6 and IL-11 in inflammation and tumorigenesis [Abstract]. Cytokine 43(3), pp. 243-243. (10.1016/j.cyto.2008.07.069)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Fielding, C. A. et al. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. Journal of Immunology 181(3), pp. 2189-2195.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Longhi, M. P. et al. 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4(2), article number: e1000006. (10.1371/journal.ppat.1000006)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Dioszeghy, V. et al. 2008. 12/15-lipoxygenase regulates the inflammatory response to bacterial products in vivo. The Journal of Immunology 181(9), pp. 6514-6524.
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
- Dimitrov, S. et al. 2006. Sleep enhances IL-6 trans-signaling in humans. The FASEB Journal 20(12), pp. 2174-2176. (10.1096/fj.06-5754fje)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Monslow, J. et al. 2006. Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. The Journal of Biological Chemistry 281(26), pp. 18043-18050. (10.1074/jbc.M510467200)
- Peake, N. J. et al. 2006. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor. Rheumatology 45(12), pp. 1485-1489. (10.1093/rheumatology/kel154)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
- Fielding, C. A. et al. 2005. Viral IL-6 blocks neutrophil infiltration during acute inflammation. The Journal of Immunology 175(6), pp. 4024-4029.
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
- McLoughlin, R. M. et al. 2004. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. The Journal of Immunology 172, pp. 5676-83.
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
- Robson, R. L., McLoughlin, R. M., Witowski, J., Loetscher, P., Wilkinson, T. S., Jones, S. A. and Topley, N. 2001. Differential regulation of chemokine production in human peritoneal mesothelial cells: IFN-gamma controls neutrophil migration across the mesothelium in vitro and in vivo. The Journal of Immunology 167(2), pp. 1028-1038.
- Hurst, S. M. et al. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14(6), pp. 705-714. (10.1016/S1074-7613(01)00151-0)
Book sections
- Millrine, D., Rice, C. M., Fernandez, J. U. and Jones, S. A. 2023. Tracking the host response to infection in peritoneal models of acute resolving inflammation. In: Jenkins, B. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York: Springer, pp. 81-95., (10.1007/978-1-0716-3331-1_7)
- Fernandez, J. U., Millrine, D. and Jones, S. 2018. Tracking competent host defence to chronic inflammation: An In Vivo model of peritonitis. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 1725. Methods in Molecular Biology New York, NY: Springer, pp. 65-75., (10.1007/978-1-4939-7568-6_6)
Ymchwil
Mae cytokines yn gyrru pathoffisioleg clefydau llidiol imiwn (IMIDs), a'u cyd-afiacheddau cysylltiedig. Mewn ymchwil nodedig, sefydlodd Jones gysyniadau newydd sy'n hyrwyddo triniaeth IMIDs gyda therapïau wedi'u targedu gan cytokine. Nododd ei ymchwil i fioleg interleukin-6 (IL-6) rôl y derbynnydd IL-6 hydawdd (IL-6 traws-signalu) mewn llid, gan egluro effeithiolrwydd clinigol a gwrtharwyddion sy'n gysylltiedig ag ataliad IL-6 (ee, tocilizumab). Sefydlodd yr astudiaethau hyn y defnydd o atalyddion dewisol traws-signalu IL-6, gan ysbrydoli ymchwil ychwanegol i gymhwyso meddyginiaethau biolegol eraill a ragnodir yn eang. Gyda chyllid gan UKRI, elusennau a diwydiant, mae ei ymchwil wedi mynd i'r afael â thair thema gysylltiedig:
1. Mae'r newid o imiwnedd cynhenid i imiwnedd addasol mewn llid – Cytokines yn siapio cwrs llid trwy hwyluso cyfathrebu rhwng leukocytes ymdreiddio a meinweoedd stromal. Nododd Jones briodweddau rheoleiddiol y derbynnydd IL-6 hydawdd (sIL-6R) yn y broses hon trwy sefydlu pwysigrwydd traws-signalu IL-6 wrth bontio imiwnedd cynhenid ac addasol (Hurst et al., 2001). Cynhyrchodd y dystiolaeth gyntaf yn vivo bod traws-signalu IL-6 yn hyrwyddo afiechyd, nododd actifyddion ffisiolegol cyntaf cynhyrchu sIL-6R a dangosodd sut mae sIL-6R sy'n siedio gan niwtroffiliaid a recriwtiwyd yn cydamseru ymatebion IL-6 rhwng celloedd stromal a leukocytes ymdreiddio (Jones et al., 1999; Hurst et al., 2001; Nowell et al., 2003; McLoughlin et al., 2005). Mae'r darganfyddiadau hyn yn egluro effeithiolrwydd therapïau wedi'u targedu gan IL-6 (ee, tocilizumab) mewn patholeg ac roeddent yn ganolog i ddatblygiad olamkicept, atalydd cyffuriau biolegol dosbarth cyntaf o draws-signalu IL-6 (Hurst et al., 2001; Nowell et al., 2003, 2009).
2. Mae'r mecanweithiau sy'n siapio imiwnopatholeg a heterogenedd clefydau– Gan ddefnyddio modelau dialysis peritoneaidd a ddatblygwyd yn ei labordy, nododd Jones sut mae heintiau rheolaidd yn peryglu homeostasis meinwe i hyrwyddo patholeg (Fielding et al., 2014). Dangosodd sut mae peritonitis dro ar ôl tro yn newid y rhwydwaith cytokine lleol sy'n rheoli llid datrys acíwt i wella gweithgareddau ffactor trawsgrifio STAT1 sy'n gyrru ffibrosis peritoneol (Jones et al., 2010; Fielding et al., 2014; Millrine et al., 2023). Yn dilyn hyn, sefydlodd Jones fod STAT1 yn siapio allbwn trawsgrifiol STAT3 mewn synovitis i lywio heterogenedd clefyd mewn arthritis gwynegol (Nowell et al., 2009; Twohig et al., 2019). Mae ei astudiaethau o fioleg IL-27 yn dangos pwysigrwydd y cydadwaith signalau hwn wrth yrru synovitis llawn lymffoid, math difrifol a heriol i'w drin o arthritis gwynegol (Jones et al., 2015). Mae'r data hyn yn sefydlu meini prawf newydd ar gyfer gwella penderfyniadau triniaeth mewn arthritis gwynegol ac maent wedi chwyldroi haenu ac astudio heterogenedd clefydau mewn synovitis.
3. Sut mae celloedd yn synhwyro ac yn dehongli ciwiau cytokine- Jones wedi nodi pwysigrwydd mecanweithiau rheoleiddio sy'n mireinio'r dehongliad mewngellol o signalau cytokine mewn clefyd. Mae ei arddangosiad bod phosphatases tyrosine protein yn gweithredu fel rheostatau signalau Jak-STAT wedi sefydlu'r mecanwaith hwn fel gyrrwr synovitis lymffoid-gyfoethog (Twohig et al., 2019). Mae hefyd wedi dangos bod llid dro ar ôl tro yn newid cydffurfiad cromatasin mewn meinweoedd stromal i ganiatáu i ffactorau trawsgrifio STAT gael mynediad at wella genynnau ffibrosis (Millrine et al., 2023). Mae'r canfyddiadau hyn yn hyrwyddo ein gwybodaeth am brosesau clefyd sy'n ddibynnol ar gyd-destun yn sylweddol, gyda Jones yn sefydlu cysyniadau newydd sy'n egluro ymatebion triniaeth i feddyginiaethau biolegol, a thueddiad genetig i IMIDs.
Bywgraffiad
Addysg:
- Hydref 1990- Rhag 1993 Ph.D. (Biocemeg) Goruchwylwyr: Yr Athro O.T.G. Jones (Adran Biocemeg, Prifysgol Bryste, Bryste, y DU) a Dr N. Topley (Sefydliad Meddygaeth Arennol, Prifysgol Cymru, Coleg Meddygaeth, Caerdydd, y DU)
- Hydref 1986 - Jun 1990 B.Sc. Gwyddorau Biolegol Cymhwysol (2.i Anrh.) Bristol Polytechnic, Bryste, UK
Trosolwg gyrfa:
- 2023: Cyd-gyfarwyddwr, Canolfan Hodge ar gyfer Niwrowyddoniaeth Drosiadol
- 2022: Cyd-gyfarwyddwr, Sefydliad Ymchwil Imiwnedd Systemau, Yr Ysgol Meddygaeth, Prifysgol Caerdydd
- 2017 - 2021: Deon Ymchwil, Yr Ysgol Meddygaeth, Prifysgol Caerdydd
- 2015 - 2020: Arweinydd Thema ar gyfer Haint, Imiwnoleg a Llid, Coleg y Gwyddorau Biofeddygol a Bywyd, Prifysgol Caerdydd
- 2012 - 2017: Cyfarwyddwr Cyswllt Ymchwil , Is-adran Heintiau ac Imiwnedd, Yr Ysgol Meddygaeth, Prifysgol Caerdydd
- 2008 - Athro Bioleg Llid, Ysgol Meddygaeth, Prifysgol Caerdydd
- 2005 - 2008: Darllenydd, Ysgol Meddygaeth , Prifysgol Caerdydd
- 2004 - 2005: Darllenydd, Ysgol y Biowyddorau , Prifysgol Caerdydd
- 2003 - 2004: Uwch Ddarlithydd, Ysgol y Biowyddorau , Prifysgol Caerdydd
- 1999 - 2003: Darlithydd, Ysgol y Biowyddorau , Prifysgol Caerdydd
- 1996 - 1998: Cymrawd Cymdeithas y Galon America, Adran Bioleg Celloedd, Prifysgol Alabama yn Birmingham, Alabama, UDA (Cyfarwyddwr: Yr Athro G.M. Fuller).
- 1994 - 1996: Cymrawd Ymchwil Sefydliad Sefydliad y Swistir, Sefydliad Theodor Kocher, Prifysgol Bern , Y Swistir (Cyfarwyddwr: Yr Athro M. Baggiolini).
Anrhydeddau a dyfarniadau
Aelod o Academia Europaea (Etholwyd Awst 2021)
Cymrawd Cymdeithas Ddysgedig Cymru (Etholwyd Mai 2019)
Cymrawd y Gymdeithas Frenhinol Bioleg (Etholwyd Mehefin 2015)
Ymchwil Iechyd a Gofal Cymru – Arweinydd Ymchwil Cyfadran (Etholwyd Mehefin 2014)
Gwobr Bolzmann 2004– Cyflwynwyd gan y Gymdeithas Cytokine Rhyngwladol (ICS) a'r Gymdeithas Ryngwladol ar gyfer Ymchwil Ymyrryd a Cytokine (ISICR) am gyfraniadau i fioleg cytokine.
Aelodaethau proffesiynol
Grwpiau Cynghori Ymchwil:
Llywodraeth
Bwrdd Addysg Uwch Cymru Brwsel (WHEB) – Datblygu Cyllid Ewropeaidd i Brifysgolion Cymru
Llysgennad Caerdydd – Cefnogi gweithgareddau masnachol yng Nghaerdydd (e.e. cysylltiadau diwydiannol, cynadleddau)
Cwmnïau fferyllol
Roche / Chugai- Aelod Panel dros Fwrdd Ymchwil Drosiadol Actemra (tocilizumab) (2008-2012)
Genentech– Bwrdd Cynghori Uwchgynhadledd Imiwnoleg Drosiadol
11 Biotherapiwteg– Cymhwyso clinigol cyffuriau biolegol EBI-029 ac EBI-031
EUSA Pharma- Defnyddio Sirukumab wrth drin canser a chyd-afiachedd cysylltiedig.
Janssen (Johnson & Johnson & GSK) – Cais clinigol Sirukumab.
NovImmune AG- Datblygu cyffuriau biolegol NI-0101 a NI-1201
Ferring Pharmaceuticals- Datblygiad clinigol Olamkicept.
Regeneron/Sanofi– Cymhwyso clinigol Sarilumab
Glaxo-Smith-Kline- Datblygu cyffuriau biolegol yn erbyn oncostatin-M ac IL-27
MAB Designs– Targedu newydd IL-6
Sector Elusen
Yn erbyn Grŵp Uwch Randdeiliaid Arthritis –
Pwyllgor Adolygu Strategaeth yn erbyn y Ganolfan Arthritis (2019-2020)
Academi'r Gwyddorau Meddygol– Gwahoddiad i grwpiau llywio ymchwil ('Hyrwyddo ymchwil i fynd i'r afael ag amlafiachedd – safbwynt y DU'; 'Amlafiachedd: blaenoriaeth ar gyfer ymchwil iechyd byd-eang'– 2018, 2019).
Aelodaeth Bwrdd Golygyddol:
Journal of Biological Chemistry (Aelod Bwrdd Golygyddol – Imiwnoleg) (2015-2021)
Ffiniau mewn Imiwnoleg (Cytokines Llidiol)
Swyddogaeth (yn gysylltiedig â Chymdeithas Ffisioleg America)
Aelodaeth y Gymdeithas:
Y Gymdeithas Biocemegol (Aelod Panel V thema; 2008-2013)
Cymdeithas Ryngwladol Cytokine ac Ymreolaethol (Aelod o'r Pwyllgor Cyfarfod; 2017-2024, Aelod o'r Pwyllgor Datblygu; 2018-2022)
Cymdeithas Ddysgedig Cymru
Academia Europaea
Cymdeithas Frenhinol Bioleg
Safleoedd academaidd blaenorol
- Chwefror 2023 - i gyflwyno. Cyd-gyfarwyddwr, Canolfan Hodge ar gyfer Niwrowyddoniaeth Drosiadol, Prifysgol Caerdydd, UK
- Ebrill 2021- i gyflwyno. Cyd-gyfarwyddwr, Sefydliad Ymchwil Imiwnedd Systemau, Prifysgol Caerdydd, UK
- Ebrill 2017- Mawrth 2021. Deon Ymchwil, Yr Ysgol Meddygaeth, Prifysgol Caerdydd
- Mawrth 2015- Medi 2020. Arweinydd Thema'r Coleg ar gyfer Haint, Imiwnoleg a Llid, Coleg y Gwyddorau Biofeddygol a Bywyd, Prifysgol Caerdydd.
- Mai 2015 - Mawrth 2017. Dirprwy Gyfarwyddwr, Is-adran Heintiau ac Imiwnedd, Yr Ysgol Meddygaeth
- Meh 2012-Mai 2015 Cyfarwyddwr Cyswllt Ymchwil ar gyfer Sefydliad Heintiau ac Imiwnedd ar gyfer Heintiau ac Imiwnedd, Yr Ysgol Meddygaeth
- Ionawr 2005 - Jul 2008 Ysgol Reader Meddygaeth, Prifysgol Caerdydd, UK
- Ionawr 2004- Rhag 2004 Darllenydd Ysgol y Biowyddorau Caerdydd, Prifysgol Caerdydd, UK
- Medi 2003- Ion 2004 Uwch Ddarlithydd Ysgol y Biowyddorau Caerdydd, Prifysgol Caerdydd, UK
- Ionawr 1999- Medi 2003 Darlithydd Ysgol y Biowyddorau Caerdydd, Prifysgol Caerdydd, UK
- 1996 - Rhagfyr 1998 Cymrawd Ymchwil Cymdeithas y Galon America Dept. o Bioleg Celloedd, Prifysgol Alabama yn Birmingham
- Ionawr 1994 - Jun 1996 Cymrawd Ymchwil Sylfaen y Swistir Theodor Kocher Institute, Prifysgol Bern, Y Swistir
Ymrwymiadau siarad cyhoeddus
Enghreifftiau o ddarlithoedd cynhadledd gwadd:
- Cyflyrau tymor hir lluosog: O Ymchwil i Realiti (2025) – siaradwr gwahoddedig, Birmingham, UK
- 12fed Cymdeithas Ryngwladol Cytokine & Interferon (2024) - Siaradwr gwahoddedig, Seoul, Korea
- 11eg Cymdeithas Ryngwladol Cytokine & Interferon (2023) - Siaradwr gwahoddedig, Athen, Gwlad Groeg
- 2il Gweithdy Rhyngwladol ar Ankylosing Spondylitis: Tales of Molecules and Patients (2023) - Siaradwr gwadd, Bellinzona, Y Swistir
- 3ydd Int. Symposiwm o Ganolfan Ymchwil Cydweithredol-877 (2022)– Siaradwr Llawn, Kiel, Yr Almaen
- Cwrs Darlith EMBO (2022) - Aelod Cyfadran, Siaradwr Llawn Gwahoddedig, Spetses, Gwlad Groeg
- Cymdeithas Ryngwladol Cytokine & Interferon (2019) - Siaradwr llawn gwahoddedig, Fienna, Awstria
- 16th Gweithdy Ymchwil Scleroderma (2019) – Siaradwr llawn gwahoddedig, Caergrawnt, UK
- 37fed Gyngres Cymdeithas Ffarmacoleg Sbaen (Partnered â Chymdeithas Ffarmacoleg Prydain) - Siaradwr llawn gwahoddedig, Barcelona, Sbaen (2017)
- Cymdeithas Brydeinig ar gyfer Rheumatoleg – Siaradwr llawn (Sesiwn a noddir gan Gymdeithas Imiwnoleg Prydain), Birmingham, UK (2017)
- Cwrdd â'r Mesotheliwm (Noddwyd: Kidney Research UK) – siaradwr gwadd, Manceinion, DU (2016)
- Cyngres Ryngwladol Imiwnoleg (2016) - siaradwr gwahoddedig, Melbourne, Awstralia
- Keystone - signalau cytokine Jak-STAT mewn clefyd imiwnedd (2016) - Siaradwr gwahoddedig, Colorado, UDA
- 12th Cyfarfod dialysis peritoneal Ewropeaidd (2015) - Siaradwr llawn gwahoddedig, Krakow, Gwlad Pwyl
- 14th Scleroderma Research Workshop (2015)– Siaradwr llawn gwahoddedig, Caergrawnt, UK
- Cymdeithas Ryngwladol Cytokine & Interferon (2014) - Siaradwr llawn gwahoddedig, Melbourne, Awstralia
- Cymdeithas Brydeinig ar gyfer Rheumatoleg (2014) – Siaradwr llawn gwahoddedig, Lerpwl, UK
- Coleg Americanaidd Rheumatoleg (2013) - Prif siaradwr llawn, San Diego, UDA
- Cynhadledd Keystone- Bioleg Cytokines a Th17 Celloedd mewn Iechyd a Chlefydau (2012), Colorado, UDA
- Prifysgol Pennsylvania, UDA, Adran Patholeg Milfeddygol – Siaradwr Gwadd (2011)
- Prifysgol Alabama yn Birmingham, UDA, Adran patholeg – Siaradwr Gwadd (2011)
- Cymdeithas Almaeneg Biocemeg a Bioleg Foleciwlaidd (2007) - Siaradwr llawn, Hamburg, yr Almaen
- Cymdeithas Awstralia ar gyfer Ymchwil Meddygol (2006) - Siaradwr llawn gwahoddedig, Melbourne, Awstralia
Enghreifftiau o gyfraniadau i raglenni addysg feddygol:
- Uwchgynhadledd Clefydau Cyfryngol a Llidiol Imiwnedd ( gyda Janssen Pharmaceuticals) - Coleg Brenhinol y Meddygon, Llundain (2017)
- Cyfarfod Rhewmatoleg Glinigol Canolbarth Lloegr– Prif Ddarlith: 'Y bioleg y tu ôl i therapi IL-6' (2017)
- CESAS Medical– 'Ystyried Interleukin-6' (un o bump siaradwr gwadd) – Llundain, y DU (2017) (gweler: https://considerations.bmj.com/content/2/1)
- Cyfarfod Rheumatoleg Glinigol Penrhyn & Hafren– Darlith wahoddedig – Taunton, Gwlad yr Haf, DU (2016)
- Cynghrair Ewropeaidd yn erbyn rhewmatiaeth: Noddodd Roche gyfarfod lloeren (2012) – Berlin, yr Almaen.
- Coleg Americanaidd Rheumatoleg: Cyfarfod lloeren a noddir gan Roche (2011) – Chicago, UDA
Sefydliad Cynadleddau Gwyddonol Rhyngwladol:
- Cynhadledd Flynyddol Cymdeithas Ryngwladol Cytokine ac Interferon ( 2026)– Cadeirydd y Pwyllgor Trefnu ar gyfer Cytokines2026 sydd ar ddod, Caerdydd, Cymru, DU
- Cynhadledd Flynyddol Cymdeithas Ryngwladol Cytokine ac Ymreolaethol (2021)– Cadeirydd y Pwyllgor Trefnu ar gyfer Cytokines2021, Neuadd y Ddinas Caerdydd, Caerdydd, Cymru, DU
- Cynhadledd Cymdeithas Ryngwladol Cytokine & Interferon (Hydref 2014) - Aelod o'r Pwyllgor Trefnu Rhyngwladol ar gyfer Cytokine 2014, Melbourne, Awstralia
- Cymdeithas Biocemegol – Aelod; Panel-V Thema (2008-12) – Adolygiad o gyfarfodydd yn Transduction Signal.
Pwyllgorau ac adolygu
Aelodaeth Panel Grant:
Cyngor Ymchwil Meddygol (UKRI)
Bwrdd Heintiau ac Imiwnedd (2020-25)
Canolfan Rhagoriaeth Ymchwil (CoRE): Panel Gwerthuso Rownd 2 (2024-25)
Pwyllgor Hyblyg COVID-19 (2020-21)
Yn erbyn arthritis.
Is-bwyllgor Ymchwil (2011-16; Cadeirydd 2015, 2016)
Pwyllgor Amlinellol Grant Rhaglen (2015, 2016)
Pwyllgor DEFNYDDIWR (Cynghorydd Gwyddonol, Panel Lleyg; 2015, 2016)
Grŵp Partneriaeth Versus Arthritis/Cancer Research UK (2018)
Is-bwyllgor Clefydau– (Is-gadeirydd 2017-20)
Ymchwil Iechyd a Gofal Cymru.
Aelod o'r Pwyllgor Grantiau (2012)
Ymchwil ar gyfer Budd Cleifion a'r Cyhoedd (Dirprwy Gadeirydd; 2013-18)
Pwyllgor Cymrodoriaethau Iechyd (2014)
Health Research Board Ireland.
Pwyllgor Elusennau Ymchwil Meddygol ar y Cyd (2016, 2018)
Prosiectau dan arweiniad ymchwilwyr (Cadeirydd 2019, 2022, 2024)
Panel Adolygu Rhwydwaith Ymchwil Methodoleg Treialon (Cadeirydd 2021)
Academi Frenhinol Iwerddon.
Panel Grant Mynediad Cynnar (2008)
Contact Details
JonesSA@caerdydd.ac.uk
+44 29206 87325
Adeilad Ymchwil Cardiofasgwlaidd Syr Geraint Evans, Llawr Ail Lawr, Ystafell 2F/02, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29206 87325
Adeilad Ymchwil Cardiofasgwlaidd Syr Geraint Evans, Llawr Ail Lawr, Ystafell 2F/02, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Themâu ymchwil
Arbenigeddau
- cytokines
- Llid
- Meddyginiaethau biolegol
- clefydau llidiol wedi'u cyfryngu gan imiwnedd
- arthritis gwynegol
